Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of NIO752 versus placebo in progressive supranuclear palsy with open-label extension
2025-523481-24-00Phase 3Authorised
- Sponsor
- Novartis
- Start
- Jun 2026
- Modality
- Vaccine mRNA → mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 13
01
Overview
Phase 3, randomised, double-blind trial in progressive supranuclear palsy (PSP) comparing NIO752 with Placebo (2 arms). Primary endpoint: Change from baseline at Week 72 in the rPSPRS-10 score. Planned start Jun 2026; status: authorised.
02
Drugs
NIO752
03
Conditions
progressive supranuclear palsy (PSP)
Beyond the preview
Go deeper on 2025-523481-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523481-24-00.